The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Haematologica. 2016 Dec;101(12):e482-e484. doi: 10.3324/haematol.2016.151449. Epub 2016 Sep 1.
No abstract available

Keywords: JAK inhibitor; anemia; myelofibrosis; overall survival; ruxolitinib.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Anemia / chemically induced
  • Anemia / drug therapy
  • Anemia / etiology*
  • Anemia / mortality*
  • Female
  • Humans
  • Male
  • Nitriles
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / mortality
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Pyrimidines

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib